Search

Search Constraints

You searched for: Author/Creator Huls, G.

Search Results

1. 212 TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY. Issue 1 (April 2015)

2. 51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY. (April 2015)

4. P437: SURVIVAL-BASED 4-GENE PROGNOSTIC INDEX IMPROVES THE ELN-RISK CLASSIFICATION IN ACUTE MYELOID LEUKEMIA. (23rd June 2022)

5. P439: ASSOCIATING EX VIVO DRUG SENSITIVITY WITH METABOLIC STATUS IDENTIFIES EFFECTIVE COMBINATION STRATEGIES IN ACUTE MYELOID LEUKEMIA. (23rd June 2022)

7. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis. (December 2018)

8. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022)

9. Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Issue 11 (18th September 2020)

10. Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Issue 11 (18th September 2020)